Platelet-Rich Plasma vs Corticosteroid Injection as Treatment for Degenerative Pathology of the Temporomandibular Joint
Ключови думи
Резюме
Описание
2.0 OBJECTIVES AND PURPOSE
2.1 The purpose of this study is to compare the efficacy, in terms of pain relief and improvement in function, of intra-articular injections with platelet rich plasma versus the current standard which is corticosteroid injections into the temporomandibular joint.
Дати
Последна проверка: | 02/28/2015 |
Първо изпратено: | 08/07/2013 |
Очаквано записване подадено: | 08/08/2013 |
Първо публикувано: | 08/11/2013 |
Изпратена последна актуализация: | 03/09/2015 |
Последна актуализация публикувана: | 03/10/2015 |
Действителна начална дата на проучването: | 10/31/2013 |
Приблизителна дата на първично завършване: | 10/31/2013 |
Състояние или заболяване
Интервенция / лечение
Drug: Group A (corticosteroid injection group)
Biological: Group B (platelet rich plasma injection)
Фаза
Групи за ръце
Arm | Интервенция / лечение |
---|---|
Active Comparator: Group A (corticosteroid injection group) Group A will receive one intra-articular injection of 2 ml of solution containing 1ml of 10mg/ml Triamcinolone suspended in 1 ml of 0.5% Bupivacaine solution per affected joint | Drug: Group A (corticosteroid injection group) |
Experimental: Group B (platelet rich plasma injection) Group B will receive a 2 ml intra-articular injection of a platelet rich plasma preparation per affected joint | Biological: Group B (platelet rich plasma injection) |
Критерии за допустимост
Полове, допустими за проучване | All |
Приема здрави доброволци | Да |
Критерии | Inclusion Criteria: The following diagnostic criteria for patient selection are to be used: - Patients will need to have a history of chronic pain (at least 3 months) refractory to conservative therapy with non-steroidal anti-inflammatory medications, muscle relaxants, diet modifications and splint therapy - Patients will also need to have imaging findings (radiography or magnetic resonance imaging) that show mild to severe degenerative changes of the temporomandibular joint Exclusion Criteria: Exclusion criteria will include - Patients with systemic disorders such as rheumatic diseases, hematologic diseases, active infections, immunosuppression - Patients receiving therapy with anticoagulants |
Резултат
Първични изходни мерки
1. Pain relief [24 weeks]
Вторични изходни мерки
1. Improvement in function [24 weeks]